About MENVEO (Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM 197 Conjugate Vaccine) GSK’s MenACWY vaccine has received regulatory approval in over 60 countries ...

The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...

with a safety profile consistent with Bexsero and Menveo. GSK’s chief scientific officer, Tony Wood, said that the results show the vaccine protects against “the broadest panel of circulating ...

Who Are the Major Players in the Menveo Market? Leading the Menveo market is GlaxoSmithKline (GSK) Plc, a key player driving innovation in vaccine development. Market leaders continually invest in ...